Literature DB >> 2117840

Pathological proteins Tau 64 and 69 are specifically expressed in the somatodendritic domain of the degenerating cortical neurons during Alzheimer's disease. Demonstration with a panel of antibodies against Tau proteins.

A Delacourte1, S Flament, E M Dibe, P Hublau, B Sablonnière, B Hémon, V Shérrer, A Défossez.   

Abstract

Bundles of paired helical filaments (PHF) accumulate in the pyramidal neurons that degenerate during Alzheimer's disease. This neurofibrillary degeneration is highly correlated with clinical signs of dementia. During the degenerating process, Tau proteins, which are the major antigenic components of PHF, are abnormally phosphorylated and two pathological isoforms named Tau 64 and 69 are expressed. We have studied their immunoblot distribution in the cortical gray and white matter from different regions of normal and Alzheimer brains, to determine if the degenerating process preferentially affects the somatodendritic or the axonal domain. Two categories of antibodies were used. The first category consisted of anti-human native Tau, anti-Tau proteins from different vertebrates, anti-PHF, monoclonal antibody Alz-50 and an anti-C terminal repeated region of Tau. In control brains, these antibodies strongly detected normal Tau proteins in the gray matter while Tau immunodetection was weak in the white matter. In Alzheimer brain cortices, each antibody detected Tau 64 and 69 in gray matter extracts but not at all in white matter extracts. The second category of anti-Tau consisted of the anti-PHF saturated with normal brain protein extracts. This antiserum only probed the abnormally phosphorylated Tau proteins. It detected Tau 64 and 69 exclusively in the cortical gray matter of Alzheimer brains. Moreover, a 55-kDa Tau protein was also immunolabelled, which might be an intermediary form between normal Tau and Tau 64 and 69. Our results demonstrate that Tau proteins are normal and major components of the somatodendritic domain and that Tau pathology, reflected by the presence of Tau 64 and 69, affects preferentially this domain during Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2117840     DOI: 10.1007/bf00308912

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  40 in total

1.  Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimer's disease.

Authors:  L A Hansen; R DeTeresa; P Davies; R D Terry
Journal:  Neurology       Date:  1988-01       Impact factor: 9.910

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 3.  The repeat region of microtubule-associated protein tau forms part of the core of the paired helical filament of Alzheimer's disease.

Authors:  T Crowther; M Goedert; C M Wischik
Journal:  Ann Med       Date:  1989       Impact factor: 4.709

4.  Phosphorylation of Tau proteins: a major event during the process of neurofibrillary degeneration. A comparative study between Alzheimer's disease and Down's syndrome.

Authors:  S Flament; A Delacourte; D M Mann
Journal:  Brain Res       Date:  1990-05-14       Impact factor: 3.252

5.  Qualitative and quantitative comparison of brain proteins in Alzheimer's disease.

Authors:  L Buee; A Laine; A Delacourte; S Flament; K K Han
Journal:  Biol Chem Hoppe Seyler       Date:  1989-11

6.  The topographic distribution of senile plaques and neurofibrillary tangles in the brains of non-demented persons of different ages.

Authors:  D M Mann; C M Tucker; P O Yates
Journal:  Neuropathol Appl Neurobiol       Date:  1987 Mar-Apr       Impact factor: 8.090

7.  Alz 50, a monoclonal antibody to Alzheimer's disease antigen, cross-reacts with tau proteins from bovine and normal human brain.

Authors:  H Ksiezak-Reding; P Davies; S H Yen
Journal:  J Biol Chem       Date:  1988-06-15       Impact factor: 5.157

8.  [Alzheimer's disease: study of the distribution of tau proteins constituting helical filament pairs in human central nervous tissue].

Authors:  M Parent; A Delacourte; A Défossez; B Hémon; K K Han; H Petit
Journal:  C R Acad Sci III       Date:  1988

9.  The monoclonal antibody, Alz 50, recognizes tau proteins in Alzheimer's disease brain.

Authors:  N Nukina; K S Kosik; D J Selkoe
Journal:  Neurosci Lett       Date:  1988-05-03       Impact factor: 3.046

10.  Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain.

Authors:  M Goedert; M G Spillantini; M C Potier; J Ulrich; R A Crowther
Journal:  EMBO J       Date:  1989-02       Impact factor: 11.598

View more
  27 in total

1.  Massive accumulation of modified tau and severe depletion of normal tau characterize the cerebral cortex and white matter of Alzheimer's disease. Demonstration using the hydrated autoclaving method.

Authors:  R W Shin; T Iwaki; T Kitamoto; Y Sato; J Tateishi
Journal:  Am J Pathol       Date:  1992-04       Impact factor: 4.307

2.  A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer's disease.

Authors:  P G Vallet; R Guntern; P R Hof; J Golaz; A Delacourte; N K Robakis; C Bouras
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

3.  Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes.

Authors:  M Mercken; M Vandermeeren; U Lübke; J Six; J Boons; A Van de Voorde; J J Martin; J Gheuens
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

4.  Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs.

Authors:  A B Rocher; J L Crimins; J M Amatrudo; M S Kinson; M A Todd-Brown; J Lewis; J I Luebke
Journal:  Exp Neurol       Date:  2009-08-07       Impact factor: 5.330

5.  Natural and experimental oral infection of nonhuman primates by bovine spongiform encephalopathy agents.

Authors:  N Bons; N Mestre-Frances; P Belli; F Cathala; D C Gajdusek; P Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 6.  Anesthesia and tau pathology.

Authors:  Robert A Whittington; Alexis Bretteville; Maya F Dickler; Emmanuel Planel
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-03-25       Impact factor: 5.067

7.  Biochemical mapping of neurofibrillary degeneration in a case of progressive supranuclear palsy: evidence for general cortical involvement.

Authors:  P Vermersch; Y Robitaille; L Bernier; A Wattez; D Gauvreau; A Delacourte
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

8.  Quantitative immunohistochemical analysis of the distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of nonagenarians and centenarians.

Authors:  P Giannakopoulos; P R Hof; M Surini; J P Michel; C Bouras
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

9.  Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration.

Authors:  H Ksiezak-Reding; K Morgan; L A Mattiace; P Davies; W K Liu; S H Yen; K Weidenheim; D W Dickson
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

10.  Neurofibrillary degeneration in amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam. Immunochemical characterization of tau proteins.

Authors:  V Buée-Scherrer; L Buée; P R Hof; B Leveugle; C Gilles; A J Loerzel; D P Perl; A Delacourte
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.